Korea FDA Mulls Detailed Biosimilar Guidelines To Boost Homegrown Firms

SEOUL - Sensing big potential for the biosimilars segment, Korea FDA has embarked upon a plan to improve its guidelines on standardization and quality that can eventually enable its homegrown companies to develop a sizeable pipeline of biosimilar products. The agency intends to implement the guidelines in 2011